Answers are grounded in this paper and cite their sources.
In the past few years, a great progress has been made in cancer immunotherapy, and it has started to change the traditional methods for tumor treatment.We have learned that multiple negative checkpoint regulators (NCRs) such as CTLA-4 and PD-1 could limit the ability of T-cell to effectively attack tumors.Targeting these NCRs has proved to be a clinically effective strategy to enhance tumor-specific immune responses.More recently, V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation (VISTA), which is expressed predominantly in the hematopoietic compartment has been identified as a new NCR. Preclinical studies with VISTA blockade have shown promising improvement in antitumor immune responses, thereby inhibiting tumor growth and improving survival.In the future, VISTA blockade may provide an immunotherapeutic strategy for human cancer.
No takes yet. Share an insight, caveat, or question.
Yujie Zhao (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: